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Synopsis
The pseudokinase mixed lineage kinase domain-like (MLKL) is an essential effector of necroptotic cell death. Two
distinct human MLKL isoforms have previously been reported, but their capacities to trigger cell death have not been
compared directly. Herein, we examine these two MLKL isoforms, and further probe the features of the human MLKL
N-terminal domain that are required for cell death. Expression in HEK293T cells of the N-terminal 201 amino acids
(aa) of human MLKL is sufficient to cause cell death, whereas expression of the first 154 aa is not. Given that aa
1–125 are able to initiate necroptosis, our findings indicate that the helix that follows this region restrains necroptotic
activity, which is again restored in longer constructs. Furthermore, MLKL isoform 2 (MLKL2), which lacks much of
the regulatory pseudokinase domain, is a much more potent inducer of cell death than MLKL isoform 1 (MLKL1)
in ectopic expression studies in HEK293T cells. Modelling predicts that a C-terminal helix constrains the activity
of MLKL1, but not MLKL2. Although both isoforms are expressed by human monocyte-derived macrophages at the
mRNA level, MLKL2 is expressed at much lower levels. We propose that it may have a regulatory role in controlling
macrophage survival, either in the steady state or in response to specific stimuli.
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INTRODUCTION
Necroptosis is a form of programmed necrotic cell death that
is triggered by specific inflammatory stimuli such as tumour
necrosis factor (TNF) [1] and Toll-like receptor (TLR) agon-
ists [2] when caspase-8 activity is concomitantly inhibited. The
lytic nature of necroptosis results in damage-associated molecu-
lar patterns (DAMPs) release [3], thus triggering potent innate
immune cell activation and inflammation. Consequently, necrop-
tosis has been linked to inflammation-linked pathology in the
intestinal tract [4–6], skin [5,7], eye [8], cardiovascular system
and brain [9]. Although specific contributions of necroptosis to
human diseases are still emerging, there has been great interest
in molecular mechanisms initiating this process.
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Initiation of necroptosis depends on the tightly regulated in-
teractions between two serine threonine kinases, receptor inter-
acting protein kinase 1 (RIP1) and RIP3, their kinase activity and
their phosphorylation [1,10–12]. The complexity of this pathway
was highlighted by a recent study showing that RIP1 can in-
hibit necroptosis during developmental processes and that RIP3-
dependent necroptosis can be activated independently of RIP1
[5]. The mixed lineage kinase domain-like (MLKL) pseudok-
inase is a RIP3 substrate and an essential molecular component of
necroptosis [13,14]. RIP3 phosphorylates MLKL at Thr-357 and
Ser-358 in human [13], and at Ser-345, Ser-347 and Thr-349 in
mouse [15]. These residues are present within the activation loop
[16] in the C-terminal pseudokinase domain of MLKL. Phos-
phorylation is believed to induce a conformational change, releas-
ing the N-terminal four-helix bundle (4HB) domain [16], which
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is indispensible for necroptotic activity [16–18]. Once activated,
MLKL can form oligomers that translocate to the plasma mem-
brane [19]. It has been proposed to disrupt membrane integrity by
increasing calcium [20] or sodium influx [18], by compromising
membranes or forming transmembrane pores [17,21,22], but the
exact mechanism(s) by which MLKL elicits cell death remain
elusive.
Human HT-29 cells were reported to express two distinct
MLKL isoforms, which are generated by alternative splicing [14].
Isoform 1 (MLKL1) consists of an N-terminal 4HB domain and
a C-terminal pseudokinase domain, which are connected by a
two-helical brace region [15,23]. Isoform 2 (MLKL2) has the
same N-terminus as MLKL1, but lacks the universal kinase core
domain, including two RIP3 phosphorylation sites on the activa-
tion loop. Since the first 125 N-terminal amino acid (aa) residues
of MLKL, which encode the 4HB domain, have been shown to
trigger cell death [16,17], our aim was to explore the ability of dif-
ferent MLKL constructs to induce cell death, including MLKL2,
which may have distinct biological functions to MLKL1.
MATERIALS AND METHODS
Constructs
Plasmids encoding human MLKL1 and MLKL2 were purchased
from DNASU Plasmid Repository and Geneservice, respectively.
Coding regions for MLKL1, N-201 (aa 1–201) and C-terminal
construct MLKL C-terminal domain (C1) (aa 155-471) were
cloned into pcDNA3.1 vector (Life Technologies) using KpnI and
XhoI (NEB) restriction sites. The construct encoding MLKL2
was used for cloning of the N-154 (aa 1–154) and N-166 (aa 1–
166) constructs and for full-length MLKL2 into the pcDNA3.1
plasmid, using BamHI and XhoI (NEB) restriction sites. All con-
structs were sequence verified. Plasmid DNA was purified using
Endofree Maxi kits (Qiagen) for use in cell-based assays. Primer
sequences used for cloning are available upon request.
Cell culture
HEK293T cells, obtained from the A.T.C.C., were cultured in
DMEM medium (Life Technologies) supplemented with 10 %
FBS (Life Technologies), 1 % GlutaMAX-I (Life Technologies),
penicillin (50 units/ml) and streptomycin (50 μg/ml) (Life Tech-
nologies) in a humidified atmosphere of 5 % CO2 and 37 ◦C. Hu-
man CD14+ monocytes were isolated from buffy coats obtained
from the Australian Red Cross Blood Service using a MACS
CD14+ positive selection kit (Miltenyi Biotech), according to
the manufacturer’s protocol. Cells were then differentiated into
human monocyte-derived macrophages (HMDM) using either
1×104 U/ml CSF-1 (Chirion) or 10 ng/ml GM-CSF (PeproTech)
for 6 days. On day 6, HMDM were harvested and plated out at
the appropriate density in RPMI 1640 medium (Life Techno-
logies) supplemented with 10 % FBS (Life Technologies), 1 %
GlutaMAX-I (Life Technologies), penicillin (50 units/ml) and
streptomycin (50 μg/ml) (Life Technologies) in the presence of
growth factor. Approval for all experiments using primary human
cells was obtained from the University of Queensland Medical
Research Ethics Committee.
Transient transfection of HEK293T
One day prior to transfection, HEK293T cells were seeded at
2×105 cells per well in 12-well plates for LDH assays, or at
1×106 cells per well in six-well plates for generating cell lys-
ates for immunoblotting. For transient transfection experiments,
Lipofectamine 2000 (Life Technologies) was used, according to
the manufacturer’s protocol.
Lactate dehydrogenase (LDH) release assay
The effects of MLKL overexpression on cell viability of
HEK293T cells was determined by lactate dehydrogenase re-
lease assays, as previously described [24]. Supernatants of trans-
fected cells were collected at 24 h post-transfection, centrifuged
for 5 min at 500 g and LDH release was measured using the LDH
Cytotoxicity Assay kit (Sigma–Aldrich), according to the manu-
facturer’s protocol. Total cellular LDH was determined by lysis
of HEK293T cells with 0.1 % Triton X-100. The absorbance at
490 nm was measured using a Powerwave XS microplate reader
(Bio-TEK), and results are presented as the percentage of the
total LDH released from cells.
Western blot analysis
Whole cell extracts were lysed on ice in RIPA buffer (150 mM
NaCl, 50 mM Tris/HCl pH 7.4, 1 % NP-40, 0.1 % SDS), sup-
plemented with complete EDTA-free protease inhibitor cocktail
(Roche). Total protein concentrations were quantified using the
BCA protein kit (Life Technologies), and cell lysates contain-
ing 20 μg of protein were subjected to electrophoretic separation
on denaturing polyacrylamide gels under reducing conditions,
followed by transfer to PVDF membranes. The latter were then
probed with a mouse anti-myc antibody (1:1000, Cell Signalling
Technologies), a rat anti-MLKL antibody (1:2000) [15] and a rab-
bit anti-GAPDH antibody (1:2500, Trevigen), followed by the ap-
propriate secondary horseradish peroxidase-conjugated antibody
(1:3000, Cell Signalling Technologies). The signal was visualized
using the chemiluminescent ECL reagent (Life Technologies).
RNA preparation and quantitative PCR analysis of
gene expression
CSF-1 or GM-CSF-differentiated HMDM were seeded on to six-
well plates at a density of 1×106 cells per well. Total RNA was
purified using a Research RNA purification mini kits (Zymo Re-
search) and treated with DNase I (Life Technologies). Superscript
III reverse transcriptase (Life Technologies) and oligo-dT primers
were used to reverse transcribe RNA into cDNA. Quantitative
RT-PCR was performed using SYBR Green (Life Technologies)
with the Viia7 (Life Technologies) detection system. All samples
were analysed in technical triplicate and results were expressed
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relative to the reference gene HPRT . Primer sequences used for
detection of MLKL1, MLKL2 and HPRT are available upon re-
quest. The specificity of MLKL1 and MLKL2 qPCR primers was
confirmed by melt curve analysis and by verifying the size of
qPCR amplicons using agarose gel electrophoresis.
Molecular modelling
The model of full-length MLKL1 was generated using Modeller
[25] with the structures PDB: 2MSV [22], PDB: 4MWI [23] and
PDB: 4BTF [15] as templates. The MLKL2 model was generated
using the I-TASSER modelling server [26]. All images were
prepared using PyMOL (DeLano Scientific LLC).
Phosphorylation site prediction
Phosphorylation sites were predicted using the online prediction
servers NetPhos 2.0 [27] and Predikin [28]. Predictions with
Predikin were made for both MLKL isoforms as RIP3 kinase
substrates.
Statistical methods
Combined data from multiple independent experiments and con-
taining at least three variables were subjected to ANOVA analysis,
followed by Dunnett’s Multiple Comparison test. A two-tailed
unpaired t test was used for comparing two data points. P-values
of <0.05 were considered as statistically significant.
RESULTS
MLKL2 has enhanced cell killing activity relative to
MLKL1
Two alternatively spliced isoforms of MLKL were reportedly
expressed by HT-29 colon human adenocarcinoma cells [14].
MLKL1 encodes the full-length 471 aa long MLKL isoform,
whereas MLKL2 lacks exons 4–8, has a longer version of exon
9, and encodes a shorter 263 aa long protein lacking much of the
pseudokinase domain (Figure 1A). To determine whether there
are differences in their biological activities, we ectopically ex-
pressed the two isoforms, as well as a number of N-terminal con-
structs of different length and a C-terminal construct (Figure 1A),
in HEK293T cells. All proteins, except the C-terminal construct
were expressed without any epitope tags. Since the monoclonal
anti-MLKL antibody used in the study by Murphy et al. [15] re-
cognizes the brace region of MLKL (see Figure 2B), a c-myc tag
was used for detection of the expressed C-terminal construct. The
MLKL1, N-166 and N-154 constructs were found to be expressed
at similar levels, whereas MLKL2 and N-201 were expressed at
much lower levels in HEK293T cells (Figure 1B). To investig-
ate whether this correlated with MLKL2 and N-201 triggering
more pronounced cell death, the effects of expression of the dif-
ferent constructs on LDH release were next assessed. Indeed,
the longest N-terminal MLKL construct tested (N-201) initiated
cell death when overexpressed in HEK293T cells, whereas the
shorter N-terminal constructs and the C-terminal construct did
not. Moreover, MLKL1 was much less effective than MLKL2 in
triggering cell death (Figure 1C). These conclusions are suppor-
ted by analysis over a concentration range, where MLKL2 was
always more active than MLKL1 (Figure 1D).
Models of human MLKL1 and MLKL2
To gain insights into potential mechanisms that might account
for differences in the activities of MLKL1 and MLKL2, models
of both isoforms were generated (Figures 2A–2C). The crystal
structure of murine MLKL revealed a 4HB domain attached to the
typical kinase-like fold with a two helix linker [15]. Since both
the N-terminal domain NMR structure [22] and the C-terminal
domain X-ray structure of human MLKL isoform 1 [23,29] were
determined separately, we used the structure of the full-length
murine protein to position them accordingly. The NMR structure
of the human N-terminal domain has revealed that there is one
additional helix (H4) that is located on the top of the 4HB, which
was not visible in the electron density of the full-length murine
structure [22]. Our model of human MLKL1 reveals that helix H4
interacts with, and fits between, helix H6 and the very last helix
of the C-terminal pseudokinase domain (Figure 2B). The model
of MLKL2, in contrast, is missing the core kinase-like domain,
whereas three α-helices, which are not part of the universal kinase
core, are present in the C-lobe of the C-terminal domain. The I-
TASSER server predicts that these three α-helices are adjacent
to the N-terminal 4HB and brace regions, making MLKL2 much
more compact than MLKL1. In this model, and in contrast with
the human MLKL1 model, the terminal C-lobe helix no longer
interacts with helix H4 (Figure 2C).
Prediction of phosphorylation sites
We analysed possible phosphorylation sites on residues of the
shorter MLKL2 that are not present in MLKL1 as a consequence
of alternative splicing and a different reading frame in exon 9.
Within this short region of 27 aa, there are seven serine residues
and one threonine residue. The NetPhos 2.0 server identified ser-
ine residues 182, 184, 187 and 205 as the most likely candidates
for phosphorylation. Of these, Ser-182, with a relative score of
68 %, was identified by Predikin server as the most likely can-
didate for phosphorylation by RIP3. For comparison, the predic-
tion scores for the experimentally determined Ser-358 and Thr-
357 phosphorylation sites in MLKL1 [13] are 75 % and 67 %,
respectively.
MLKL1 is expressed at higher levels as compared
with MLKL2 in HMDM
The observed difference in cell killing activity between the two
MLKL isoforms led us to investigate their expression patterns.
Since macrophages are exquisitely sensitive to TLR ligands and
TNF, both of which can trigger necroptosis upon loss of caspase-
8 function, we assessed expression of each isoform in HMDM.
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Figure 1 Human MLKL2 is a more potent inducer of cell death than MLKL1, and the N-154 construct has no biological
activity when expressed ectopically
(A) Schematic representation of theMLKL1 andMLKL2mRNA transcripts, and different humanMLKL expression constructs
used for overexpression in HEK293T cells. Colour codes are as in Figure 2. (B) HEK293T cells were transfected with
different human MLKL constructs (100 ng) or an empty vector (EV) control (100 ng). Total cell lysates were collected at
12 h post-transfection and subjected to immunoblotting. GADPH was used as a loading control. Data are representative
of three independent experiments. (C) HEK293T cells were transfected with EV or human MLKL expression constructs, as
shown in (A). Cell viability was determined at 24 h post-transfection by LDH release assays. Shown is the mean+S.E.M.
of six independent experiments. (D) HEK293T were transfected with increasing amounts of expression plasmids encoding
human MLKL1, MLKL2 or N-201, with the total amount of transfected DNA being kept constant with EV. LDH release was
measured at 24 h post-transfection. Shown is mean+S.E.M. of three independent experiments. *P0.05, **P0.01,
***P0.001, ****P0.0001.
Using quantitative real-time PCR with transcript-specific
primers, we found that MLKL1 and MLKL2 are expressed by
both CSF-1- and GM-CSF-derived HMDM at the mRNA level.
However, basal levels of MLKL1 mRNA were ∼10-fold higher
than those of MLKL2 (Figure 3).
DISCUSSION
Although MLKL is essential for necroptosis [13,15,30], the ex-
act mechanisms by which it initiates this process remain unclear.
The N-terminal 4HB domain of both human and mouse MLKL
(aa 1–125) is sufficient to trigger necroptosis [16–18], and the
same has been demonstrated for N-terminal regions spanning
the first 180 or 210 aa of human MLKL [17], and 180 aa for
mouse MLKL [16]. Somewhat surprisingly, the expression of the
N-terminal 167 residues was reported to have no necroptotic
activity [17]. Similarly, we found that N-166 did not trigger cell
death, whereas the N-201 construct was active (Figure 1C). Su
et al. [22] presented the NMR structure of the first 2–154 aa of
human MLKL, and reported that the encoded protein induced
liposome leakage, although more slowly than the 4HB construct,
leading to the conclusion that H6 α-helix, the first helix of the
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Figure 2 Human MLKL2 lacks the major part of the kinase-like domain that is present in MLKL1
The N-terminal 4HB is shown in blue, the brace region in pink and the pseudokinase domain in orange, red and
yellow. The regions that differ in MLKL1 compared with MLKL2 are shown in orange. Known phosphorylation sites in
MLKL1 and putative phosphorylation sites in MLKL2 are shown in green. Helices H4, H6 and MLKL C-terminal helix (Hc)
are shown in cyan, magenta and yellow, respectively. (A) Sequence comparison of MLKL1 and MLKL2. (B) Human MLKL1
model. (C) Human MLKL2 model.
‘brace’ region, inhibits this activity. In our experiments, we ob-
served that neither the N-154 nor N-166 construct triggered cell
death in HEK293T cells. Since both constructs include the H6
α-helix, our findings support the view that this region constrains
necroptotic activity. Necroptotic activity is restored in longer con-
structs (180, 201, 210 aa), suggesting that a region C-terminal to
the helix H6 is needed to facilitate pulling this helix away from the
4HB, thus unleashing its activity. Similarly, activation of mouse
MLKL occurs by phosphorylation of the pseudokinase domain
activation loop, which liberates 4HB, causing cell death [16].
In human MLKL, residues Thr-357 and Ser-358 are phos-
phorylated [13,21], and their mutation inhibits the necroptotic
activity of MLKL1 [13]. The alternatively spliced MLKL2 is
208 aa shorter than MLKL1, and lacks a substantial part of the
pseudokinase domain, including the identified phosphorylation
sites [13,14]. Hildebrand et al. [16] proposed that the C-terminal
pseudokinase domain acts as a suppressor of MLKL-mediated
cell death until activated. This probably explains the enhanced
capacity of MLKL2, as compared with MLKL1, to initiate cell
death. Our molecular models provide a plausible explanation for
these differences. In the MLKL1 model (Figure 2B), the core
C-lobe of the kinase-like domain structurally supports the last
C-terminal helix that stabilizes the helices H4 and H6. This is
not the case in the MLKL2 model (Figure 2C) and, even if the
positioning of the C-terminal helix is not predicted correctly, it
is unlikely that it would adopt the same position as in MLKL1,
without the aid of the missing core kinase-like domain. Helix
H4 is evidently important for the effector function of MLKL,
since binding of necrosulfonamide to Cys86 in the middle of
helix H4 inhibits necroptosis [13], as well as the liposome
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Figure 3 MLKL1 is expressed at higher levels than MLKL2 in
HMDM
Quantitative PCR primers specifically detecting human MLKL1 and
MLKL2 were used to quantify mRNA levels relative to HPRT in CSF-1-
and GM-CSF-derived HMDM. Data represent mean+S.E.M. of three in-
dependent experiments *P0.05, **P0.01; by two-tailed unpaired
t test.
permeabilization activities of MLKL1 [21] and MLKL (2–154)
[22]. The hydrophobic face of helix H4 is stabilized by helix
H6, which as discussed above, inhibits this activity. The lack
of interactions between the last C-terminal helix with helices
H4 and H6 in MLKL2 probably explains the more potent biolo-
gical activity of MLKL2. It also suggests that destabilization of
this region is important for triggering MLKL effector function.
Thus, the absence of the core kinase-like domain in MLKL2 may
render it necroptotically active without requiring RIP3-dependent
activation, as was observed when the 4HB domain alone was ex-
pressed in cells [16,17]. Alternatively, the activation of MLKL2
may depend on some yet to be identified phosphorylation event.
A recent study has identified additional residues outside the ac-
tivation loop in mouse MLKL that are subject to phosphoryla-
tion, which can enhance or even suppress MLKL activation [31].
There are eight possible phosphorylation sites, in the short 27
aa region that is unique to MLKL2, any of which might con-
tribute to their fine tune MLKL2 necroptotic activity. It thus
remains of interest to determine whether phosphorylation of
one or more of these residues can modulate MLKL2-induced
cell death and, if so, which kinases are responsible for these
events.
In the presence of pan-caspase inhibitors, some TLR agon-
ists [30], as well as bacterial pathogens [32], trigger necroptosis
of mouse macrophages. Necroptosis has not been well studied
in human macrophages, although a single publication showed
that treatment with LPS and caspase inhibitors did cause cell
death [33]. We find that both MLKL isoforms are expressed in
human macrophages and that the basal expression of MLKL1
mRNA is ∼10-fold higher than that of MLKL2. Whether this
level of MLKL2 expression is sufficient to regulate survival of
macrophages in the steady state is unknown. It may be that other
stimuli up-regulate MLKL2 expression and/or promote MLKL2
serine phosphorylation in macrophages to unleash its biological
activity. Such a conclusion is supported by the findings of a previ-
ous study; in a comparison of HT-29 clones with either MLKL1
or both MLKL1 and MLKL2 stably silenced by shRNAs, knock-
down of MLKL1 alone was sufficient to protect against TNF-
induced necroptotic cell death [14]. This suggests that MLKL1
has a dominant role in TNF-triggered necroptosis, at least under
these experimental conditions. Future studies should therefore
address the external stimuli and intracellular signalling events
that promote MLKL2 expression and/or activation.
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